Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3194210 | 1.00 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL13481736 | 1.00 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL6121812 | 0.91 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL21430191 | 0.91 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL21527750 | 0.91 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL6121804 | 0.91 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL6186427 | 0.91 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL19853319 | 0.90 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL19853293 | 0.90 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL29015468 | 0.88 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902693-B2 | Preparation method for pyrrolidine-2-carboxylic acid derivatives | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
| US-20160145208-A1 | Preparation method for pyrrolidine-2-carboxylic acid derivatives | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145208-A1 | Preparation method for pyrrolidine-2-carboxylic acid derivatives | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2016-05-26 | — | — | US | disclosed |
| US-20110039899-A1 | Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-20110039899-A1 | Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-20110039899-A1 | Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| EP-2196201-A2 | Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms | Warner-Lambert Company LLC (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-2196201-A2 | Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms | Warner-Lambert Company LLC (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-1558246-B1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LTD (GB) | 2010-05-19 | — | — | EP | disclosed |
| EP-1558246-B1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LTD (GB) | 2010-05-19 | — | — | EP | disclosed |
| EP-1572173-A1 | ALPHA-2-DELTA LIGAND TO TREAT LOWER URINARY TRACT SYMPTOMS | Warner-Lambert Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040180958-A1 | Method of treatment | PFIZER PRODUCTS INC. | 2004-09-16 | — | — | US | disclosed |
| US-20040176456-A1 | Method of treatment for sexual dysfunction | TAYLOR CHARLES PRICE (US) | 2004-09-09 | — | — | US | disclosed |
| US-20040143014-A1 | Therapeutic use of alpha-2-delta ligands | PFIZER INC | 2004-07-22 | — | — | US | disclosed |
| US-20040132801-A1 | Therapeutic proline derivatives | RAWSON DAVID JAMES (GB) | 2004-07-08 | — | — | US | disclosed |
| WO-2004054577-A1 | ALPHA-2-DELTA LIGANDS TO TREAT OCD AND RELATED DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054560-A1 | ALPHA-2-DELTA LIGAND TO TREAT LOWER URINARY TRACT SYMPTOMS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054560-A1 | ALPHA-2-DELTA LIGAND TO TREAT LOWER URINARY TRACT SYMPTOMS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054563-A1 | ALPHA-2-DELTA LIGAND FOR THE TREATMENT OF SEXUAL DYSFUNCTION | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004039367-A1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LIMITED (GN) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176456-A1 | Method of treatment for sexual dysfunction | SHBG, CHRND, ADRB2 | HSD17B10 1421/4885SMN1; SMN2 1150/4885BTK 4327/4885 |
| US-20110039899-A1 | Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH | GABRB2, GABRB3, GABRB1 | HSD17B10 1151/4885SMN1; SMN2 3841/4885BTK 4664/4885 |
| US-20040132801-A1 | Therapeutic proline derivatives | PRRC2C, SLC6A7, FAAH | HSD17B10 1366/4885SMN1; SMN2 91/4885BTK 3535/4885 |
| US-20160145208-A1 | Preparation method for pyrrolidine-2-carboxylic acid derivatives | PDHB, HPD, PYCR1 | HSD17B10 950/4885SMN1; SMN2 2565/4885BTK 3835/4885 |
| US-20040180958-A1 | Method of treatment | BPHL, ADRA2B, ADRB2 | HSD17B10 620/4885SMN1; SMN2 3588/4885BTK 4827/4885 |
| US-20040143014-A1 | Therapeutic use of alpha-2-delta ligands | CHRND, CHRNG, CHRNE | HSD17B10 2473/4885SMN1; SMN2 4235/4885BTK 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.